Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer.
Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A, Parker BS. Rautela J, et al. Cancer Immunol Res. 2015 Nov;3(11):1207-17. doi: 10.1158/2326-6066.CIR-15-0065. Epub 2015 Jul 21. Cancer Immunol Res. 2015. PMID: 26198985
CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Delconte RB, Kolesnik TB, Dagley LF, Rautela J, Shi W, Putz EM, Stannard K, Zhang JG, Teh C, Firth M, Ushiki T, Andoniou CE, Degli-Esposti MA, Sharp PP, Sanvitale CE, Infusini G, Liau NP, Linossi EM, Burns CJ, Carotta S, Gray DH, Seillet C, Hutchinson DS, Belz GT, Webb AI, Alexander WS, Li SS, Bullock AN, Babon JJ, Smyth MJ, Nicholson SE, Huntington ND. Delconte RB, et al. Among authors: rautela j. Nat Immunol. 2016 Jul;17(7):816-24. doi: 10.1038/ni.3470. Epub 2016 May 23. Nat Immunol. 2016. PMID: 27213690
IL-15 signaling in NK cell cancer immunotherapy.
Rautela J, Huntington ND. Rautela J, et al. Curr Opin Immunol. 2017 Feb;44:1-6. doi: 10.1016/j.coi.2016.10.004. Epub 2016 Nov 11. Curr Opin Immunol. 2017. PMID: 27835762 Review.
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.
Young A, Ngiow SF, Madore J, Reinhardt J, Landsberg J, Chitsazan A, Rautela J, Bald T, Barkauskas DS, Ahern E, Huntington ND, Schadendorf D, Long GV, Boyle GM, Hölzel M, Scolyer RA, Smyth MJ. Young A, et al. Among authors: rautela j. Cancer Res. 2017 Sep 1;77(17):4684-4696. doi: 10.1158/0008-5472.CAN-17-0393. Epub 2017 Jun 26. Cancer Res. 2017. PMID: 28652244
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.
Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, Rautela J, Straube J, Waddell N, Blake SJ, Yan J, Bartholin L, Lee JS, Vivier E, Takeda K, Messaoudene M, Zitvogel L, Teng MWL, Belz GT, Engwerda CR, Huntington ND, Nakamura K, Hölzel M, Smyth MJ. Gao Y, et al. Among authors: rautela j. Nat Immunol. 2017 Sep;18(9):1004-1015. doi: 10.1038/ni.3800. Epub 2017 Jul 31. Nat Immunol. 2017. PMID: 28759001
Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.
Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS. Brockwell NK, et al. Among authors: rautela j. Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28. Cancer Immunol Res. 2017. PMID: 28848054
46 results